The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease

Trial Profile

The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Biomarker; Pharmacodynamics
  • Acronyms WELCOME
  • Most Recent Events

    • 22 Apr 2016 Results published in the Diabetologia
    • 14 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017.
    • 14 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top